94 related articles for article (PubMed ID: 18365550)
21. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
[TBL] [Abstract][Full Text] [Related]
22. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
23. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
[TBL] [Abstract][Full Text] [Related]
24. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
25. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.
Gameiro P; Vieira S; Carrara P; Silva AL; Diamond J; Botelho de Sousa A; Mehta AB; Prentice HG; Guimarães JE; Hoffbrand AV; Foroni L; Parreira A
Haematologica; 2001 Jun; 86(6):577-85. PubMed ID: 11418366
[TBL] [Abstract][Full Text] [Related]
26. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
28. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
29. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
30. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs.
Gentilini F; Turba ME; Forni M
Vet Immunol Immunopathol; 2013 Jun; 153(3-4):279-88. PubMed ID: 23602204
[TBL] [Abstract][Full Text] [Related]
31. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
32. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
33. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
34. [The clinical significance of minimal residual disease of acute leukemia with t(4;11) (q21;q23)].
Okamura T; Park YD; Inoue M; Yasui M; Ueno M; Endo C; Yagi K; Kawa K
Rinsho Ketsueki; 1996 Nov; 37(11):1318-21. PubMed ID: 8960669
[TBL] [Abstract][Full Text] [Related]
35. Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines.
Li CC; O'Connell CD; Beckwith M; Longo DL
Leukemia; 1995 Apr; 9(4):650-5. PubMed ID: 7723400
[TBL] [Abstract][Full Text] [Related]
36. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
[TBL] [Abstract][Full Text] [Related]
37. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
[TBL] [Abstract][Full Text] [Related]
38. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli RM; Bandini G; Motta MR; Testoni N; Amabile M; Ottaviani E; Vianelli N; de Vivo A; Gozzetti A; Tura S; Cavo M
J Clin Oncol; 2000 Jun; 18(11):2273-81. PubMed ID: 10829048
[TBL] [Abstract][Full Text] [Related]
39. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.
Gribben JG; Neuberg D; Freedman AS; Gimmi CD; Pesek KW; Barber M; Saporito L; Woo SD; Coral F; Spector N
Blood; 1993 Jun; 81(12):3449-57. PubMed ID: 8507880
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study.
Yamazaki J; Takahashi M; Setoguchi A; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2010; 24(4):897-903. PubMed ID: 20492493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
